Stocks Health care ENDV
OTC · Health careEndonovo Therapeutics, Inc. (ENDV)
Endonovo Therapeutics, Inc. brought in $255.7K of revenue over the twelve months to September 30, 2023, up 1,699.9% from a year earlier. It posted a net loss of $4.4M. At September 30, 2023 it held $0 in cash against $7.1M of debt. Its latest periodic report to the SEC is the quarterly report (amended) (10-Q/A) filed on December 29, 2023.
Watch ENDV in 60 secondsWhat Endonovo Therapeutics, Inc. does
Endonovo Therapeutics, Inc. is registered with the SEC under industry code SIC 3845 (Electromedical & Electrotherapeutic Apparatus). Its shares trade on OTC under the ticker ENDV.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2022 | $135.4K | -$18.5M | -$0.13 | n/a |
| 2021 | $73.1K | -$3.1M | -$0.05 | n/a |
| 2020 | $165.8K | -$395.6K | -$0.03 | n/a |
| 2019 | $310.2K | -$17.3M | -$24.83 | -$2.5M |
| 2018 | $83.3K | -$6.4M | -$17.76 | -$2.9M |
| 2017 | n/a | -$10.8M | -$35.52 | n/a |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Endonovo Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 19, 2024Form SEC STAFF ACTION filing SEC STAFF ACTION
- February 2, 2024Deregistration 15-12G
- January 3, 2024
- December 29, 2023Quarterly report (amended) 10-Q/A · period to September 30, 2023Revenue fell 86% to $1.5K versus the same quarter last year; diluted EPS $0.00 versus $0.00.
- December 29, 2023Quarterly report 10-Q · period to September 30, 2023Revenue fell 86% to $1.5K versus the same quarter last year; diluted EPS $0.00 versus $0.00.
- December 4, 2023
- November 15, 2023Late quarterly report notice NT 10-Q
- October 12, 2023Other event 8-K
- August 25, 2023Form 1-A/A filing 1-A/A
- August 21, 2023Quarterly report 10-Q · period to June 30, 2023Revenue rose 6,854% to $45.2K versus the same quarter last year; diluted EPS -$0.01 versus -$0.02.
Questions about ENDV
What does Endonovo Therapeutics, Inc. do?
Endonovo Therapeutics, Inc. is registered with the SEC under industry code SIC 3845 (Electromedical & Electrotherapeutic Apparatus). Its shares trade on OTC under the ticker ENDV.
Is Endonovo Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2023 it reported a net loss of $4.4M on revenue of $255.7K.
How much revenue does Endonovo Therapeutics, Inc. make?
Over the twelve months to September 30, 2023 Endonovo Therapeutics, Inc. reported revenue of $255.7K. That is 1,699.9% more than a year earlier.
When did Endonovo Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (amended) (10-Q/A) filed on December 29, 2023. It covers the period to September 30, 2023. Its newest filing of any kind is the form SEC STAFF ACTION filing from September 19, 2024.
Similar companies
Compare ENDV with
Follow ENDV
Get an email when Endonovo Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ENDV: get an email when it filesWhere the numbers come from
Financial figures are the values Endonovo Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.